Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Disrupted in Renal Carcinoma 2 (DIRC2) (Middle Region) Peptide

DIRC2 Hôte: Synthetic BP, WB
N° du produit ABIN8098989
168,15 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination: France
Envoi sous 6 à 9 jours ouvrables

Aperçu rapide pour Disrupted in Renal Carcinoma 2 (DIRC2) (Middle Region) Peptide (ABIN8098989)

Antigène

DIRC2 (Disrupted in Renal Carcinoma 2 (DIRC2))

Source

  • 2
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Fonction

    DIRC2 Peptide - middle region
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Commentaires

    This is a synthetic peptide designed for use in combination with anti-DIRC2 antibody ( ARP50133_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Buffer

    Lyophilized powder

    Stock

    -20 °C

    Stockage commentaire

    For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
  • Antigène

    DIRC2 (Disrupted in Renal Carcinoma 2 (DIRC2))

    Sujet

    Background Information: DIRC2 is a membrane-bound protein from the major facilitator superfamily of transporters. Disruption of DIRC2 by translocation has been associated with haplo-insufficiency and renal cell carcinomas. Alternatively spliced transcript variants have been described, but their biological validity has not yet been determined.This gene encodes a membrane-bound protein from the major facilitator superfamily of transporters. Disruption of this gene by translocation has been associated with haplo-insufficiency and renal cell carcinomas. Alternatively spliced transcript variants have been described, but their biological validity has not yet been determined. Sequence Note: The RefSeq transcript and protein were derived from genomic sequence and transcripts to make the sequence consistent with the reference genome assembly. The genomic coordinates used for the transcript record were based on alignments.

    Alternative Symbols: FLJ14784, RCC4

    Poids moléculaire

    52kDa

    ID gène

    84925

    NCBI Accession

    NP_116228

    UniProt

    Q96SL1
Vous êtes ici:
Chat with us!